scPharmaceuticals Inc（SCPH）资讯与事件SCPHscPharmaceuticals Inc

MannKind to purchase scPharmaceuticals for as much as $6.35 per share in cash

MannKind Corporation (MNKD) and scPharmaceuticals (SCPH) announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals. This proposed acquisition marks MannKind's strategic expansion into cardiorenal medicine, establishing the company's cardiometabolic business alongside its orphan lung division. scPharmaceuticals currently markets FUROSCIX, an FDA-approved on-body infuser delivering furosemide, the gold standard to treat fluid overload in adult patients with chronic heart failure and chronic kidney disease. The estimated total addressable market opportunity equates to more than $10B in the U.S. alone. scPharmaceuticals has demonstrated strong commercial momentum with its 2024 sales force expansion, ongoing launch into nephrology and accelerating growth in integrated delivery networks. For the six months ended June 30, 2025, net sales totaled $27.8M, up 96% year-over-year. The FUROSCIX ReadyFlow Autoinjector is on track for a Q3 2025 supplemental New Drug Application submission, potentially enabling patients to reduce treatment time from five hours to less than 10 seconds. Under the terms of the definitive merger agreement, MannKind will promptly commence a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock at a price of $5.35 per share in cash at closing plus one non-tradable CVR per share to receive certain milestone payments of up to an aggregate of $1.00 per CVR in cash, for total consideration of up to $6.35 per share in cash, representing a total equity value of approximately $303 million at closing and representing a total deal value of up to approximately $360M. The non-tradable CVR is payable upon achieving certain regulatory and net sales milestones. The transaction is expected to close in the fourth quarter of 2025, subject to receipt of applicable regulatory approvals and the satisfaction of other customary conditions. As a condition to funding the Blackstone financing, upon the closing of the transaction, MannKind will be obligated to repay and extinguish all outstanding indebtedness of scPharmaceuticals under its credit facility with Perceptive and buy-out Perceptive's rights to receive revenue payments pursuant to its revenue purchase and sale agreement, which is estimated to equal an aggregate repayment and buyout amount of $81M, assuming a closing on September 30, 2025.

scPharmaceuticals receives Notices of Allowance from USPTO for SCP-111

scPharmaceuticals announced that it has received five Notices of Allowance from the United States Patent and Trademark Office, USPTO, for patent applications covering their latest furosemide formulation, SCP-111. The SCP-111 formulation is the subject of a supplemental NDA expected to be filed by the Company this quarter. The five patents, once issued, will join four additional patents owned by the Company that cover the SCP-111 formulation. "These allowances are vital developments in scPharmaceuticals' pursuit to provide effective care to patients suffering from edema due to heart failure or chronic kidney disease," said John Tucker, Chief Executive Officer of scPharmaceuticals. "Securing additional patent protection represents a key strategic achievement that strengthens the Company's intellectual property portfolio, which I believe supports the advancement of next-generation formulations and reinforces our commitment to delivering transformative outcomes for patients while expanding market opportunities."